Profound Medical (PROF) Stock Price, News & Analysis

Company Overview

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: $5.92 to $6.20
• 50-Day Range: $6.00 to $8.54
• 52-Week Range: $5.92 to $11.42
• Volume: 36,338 shs
• Average Volume: 71,974 shs
• Market Capitalization: $180.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.25
• Consensus Rating: Buy

Profound Medical Stock Analysis - MarketRank™

Profound Medical scored higher than 36% of companies evaluated by MarketBeat, and ranked 516th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Profound Medical has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Profound Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Profound Medical are expected to grow in the coming year, from ($1.15) to ($0.73) per share.

Price to Book Value per Share Ratio

Profound Medical has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

1.27% of the outstanding shares of Profound Medical have been sold short.

Short Interest Ratio / Days to Cover

Profound Medical has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Profound Medical has recently increased by 3.33%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Profound Medical does not currently pay a dividend.

Dividend Growth

Profound Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.27% of the outstanding shares of Profound Medical have been sold short.

Short Interest Ratio / Days to Cover

Profound Medical has a short interest ratio ("days to cover") of 5.3.

Change versus previous month

Short interest in Profound Medical has recently increased by 3.33%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for PROF on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Profound Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.52% of the stock of Profound Medical is held by insiders.

Percentage Held by Institutions

47.86% of the stock of Profound Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PROF Stock Analysis - Frequently Asked Questions

How have PROF shares performed this year?

Profound Medical's stock was trading at $7.51 at the start of the year. Since then, PROF shares have decreased by 20.1% and is now trading at $6.00.
View the best growth stocks for 2025 here.

How were Profound Medical's earnings last quarter?

Profound Medical Corp. (NASDAQ:PROF) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.05. The company had revenue of $2.83 million for the quarter, compared to analyst estimates of $3.30 million. Profound Medical had a negative trailing twelve-month return on equity of 85.22% and a negative net margin of 349.41%.

Who are Profound Medical's major shareholders?

Profound Medical's top institutional investors include Gagnon Securities LLC (5.50%), Gagnon Advisors LLC (2.98%), Raymond James Financial Inc. (2.92%) and MMCAP International Inc. SPC (1.63%).

How do I buy shares of Profound Medical?

Shares of PROF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Profound Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Profound Medical investors own include Block (SQ), Alibaba Group (BABA), Pfizer (PFE), NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA) and DocuSign (DOCU).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/09/2025
• Next Earnings (Estimated): 3/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PROF
• CUSIP: N/A
• CIK: 1628808
• Web: www.profoundmedical.com
• Phone: (647) 476-1350
• Fax: 64-7847-3739
• Employees: 150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.25
• High Stock Price Target: $16.50
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +137.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-28,570,000.00
• Net Margins: -349.41%
• Pretax Margin: -349.33%
• Return on Equity: -85.22%
• Return on Assets: -64.87%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 6.12
• Quick Ratio: 5.16

Sales & Book Value

• Annual Sales: $7.20 million
• Price / Sales: 25.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.28 per share
• Price / Book: 4.69

Miscellaneous

• Outstanding Shares: 30,040,000
• Free Float: 29,583,000
• Market Cap: $180.24 million
• Optionable: Optionable
• Beta: 0.88